News und Analysen
![Premier Inc. to Report Fiscal 2020 Second-Quarter Results and Host Conference Call Before Market Opens on February 4](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Premier Inc. to Report Fiscal 2020 Second-Quarter Results and Host Conference Call Before Market Opens on February 4
Premier Inc. (NASDAQ: PINC) plans to report fiscal 2020 second-quarter financial results the morning of Feb. 4, 2020, followed by a conference call at 8 a.m. ET to discuss the results.
Conference
![Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI’s sequencing products, including the DNBSeq-400 (also known as MGISeq-2000)
![Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI’s sequencing products, including the DNBSeq-400 (also known as MGISeq-2000)
![Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI’s sequencing products, including the DNBSeq-400 (also known as MGISeq-2000)
![Applied Genetic Technologies: Kursfeuerwerk nach guten Studiendaten!](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Applied Genetic Technologies: Kursfeuerwerk nach guten Studiendaten!
Zu einem regelrechten Kursfeuerwerk kam es gestern bei der Aktie von Applied Genetic Technologies (WKN: A110V2), der Kurs konnte sich gestern von 4,16 auf 9,27 USD mehr als verdoppeln.
Grund für
![Quidel Announces Preliminary Revenue for Fourth Quarter 2019](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Quidel Announces Preliminary Revenue for Fourth Quarter 2019
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 8, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
![Morphosys: Beste Perspektiven](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Morphosys: Beste Perspektiven
Der Morphosys-Konzern (WKN: 663200) meldete sich zuletzt mit wichtigen medizinischen Updates, die es aufgrund ihrer Signifikanz zu beleuchten gilt.
Der Initiation der Phase 1-Studie von Tafasitamab
![Morphosys: Beste Perspektiven](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Morphosys: Beste Perspektiven
Der Morphosys-Konzern (WKN: 663200) meldete sich zuletzt mit wichtigen medizinischen Updates, die es aufgrund ihrer Signifikanz zu beleuchten gilt.
Der Initiation der Phase 1-Studie von Tafasitamab
![Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare
![Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform
![Evotec: Es regnet Millionen dank Bayer – wieder mal!](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Evotec: Es regnet Millionen dank Bayer – wieder mal!
Vor zwei Tagen machte Evotec (WKN: 566480) die Erweiterung seiner iPSC-Allianz mit Bristol-Myers Squibb öffentlich (wir berichteten). Heute meldet der Hamburger Biotechkonzern eine „neue
![Mauna Kea Technologies Announces Publication of Positive Results on Needle-Based Endomicroscopy for the Clinical Management of Pancreatic Cystic Lesions](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Mauna Kea Technologies Announces Publication of Positive Results on Needle-Based Endomicroscopy for the Clinical Management of Pancreatic Cystic Lesions
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today
![Healthcare Improvement Company Premier Inc. to Present at 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 14](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Healthcare Improvement Company Premier Inc. to Present at 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 14
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that its Chief Executive Officer, Susan DeVore, will present at the 38th Annual J.P. Morgan Healthcare
![Application Process for 2020 Louisville-Based Community Partners Program Opens](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Application Process for 2020 Louisville-Based Community Partners Program Opens
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 38 years, today announced the details of its 2020 Community Partners Program. Through this initiative, The Humana
![Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases
![Evotec: Das hören Anleger gern](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Evotec: Das hören Anleger gern
Es sind Meldungen wie diese, die Anleger in Evotec-Aktien (WKN: 566480) jubeln lassen. Wie gestern bekannt gegeben, erweitert Evotec die Forschungsallianz mit dem Global Player Bristol-Myers Squibb
![Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
![NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update
Regulatory News:
“After the achievement of major development milestones in 2019, 2020 offers great opportunity for Nanobiotix and NBTXR3 to fulfill unmet patient needs across oncology. Given
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 38th Annual J.P. Morgan
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 38th Annual J.P. Morgan
![Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019
Clovis
Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary,
unaudited revenues for the fourth quarter and full year ended December
31, 2019. The financial
![Clovis Oncology Announces Debt Refinancing Transaction](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clovis Oncology Announces Debt Refinancing Transaction
Clovis Oncology, Inc. (NASDAQ: CLVS) (the “Company”) announced today that on January 6, 2020 it priced a registered direct offering (the “Share Offering”) of an aggregate of 17,777,679 shares (the
![Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:
![The Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
The Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75%